PDC*line Pharma

PDC*line Pharma is a clinical stage biotech company developing a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens.

PDC*line Pharma's cancer vaccine contains proprietary, potent, and scalable plasmacytoid dendritic cell line (PDC*line), whose remarkable characteristics make them excellently suited for immunotherapy.

PDC*line Pharma was foundedas a spin-off of the French Blood Bank (EFS) in 2014, by Laurent Levy and Joel Plumas. The company is headquartered in Liège, Liège, Belgium, with an office in La Tronche, Grenoble, France.


PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors.


PDC*line is very easy to expand in large quantities in bioreactors (no need of maturation factors) and having been exposed in vitro to targeted tumor antigens and irradiated, it can be stored for years.


PDC*line Pharma granted exclusive license in South Korea and exclusive option in other Asian countries to LG Chem Life Sciences Company, for the development and commercialization of PDC*lung cancer vaccine for lung cancer.


PDC*line is backed by SFPI, NOSHAQ, Korean Investment Partners, Alpha Holdings, Shinhan-Cognitive Start-up Fund, SRIW, Brain Asset Management and Hansongneotech, and others. The company raised €17.5M in Series B2 round on Dec 06, 2021. This brings PDC*line's total funding to €49M to date.



  • Year founded: 2014
  • Funding Info: €49M over 4 Rounds (Latest Funding Type: Series B2)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Liège
  • State: Liège
  • Country: Belgium
Related businesses